Karl-Johan Jakola, Chairman
Karl-Johan Jakola is managing partner of NorInnova Forvaltning AS, and has been heavily involved in business development and as investor in start-up companies. He has a bachelor and background from University of Tromsø in biology, chemistry, computer science and law and a bachelor in economy from Bodø University College. He has long experience as board member in many Companies.
Øivind Enger, Vice Chair
Øivind is Partner Investment Advisor in Sarsia Seed AS. Dr. Enger has a Ph.D. in microbiology and over 13 years of research experience in molecular biology and fish diseases, and many years of experience in commercializing research-based projects in biology, aqua culture, medicine and biotechnology. Dr. Enger has several years of managerial and board experience from his positions at Sarsia Innovation AS and Sarsia Seed AS.
Sveinung brings 15 years of leadership and board experience from a variety of businesses, including business entrepreneurial know-how obtained as Managing Partner at Sarsia Seed AS, from the health-care sector, regional MD and strategy director at the Berlitz corporation, general manager, marketing and strategy director positions within the Telenor corporation, and director at the joint departments of anesthesia, intensive care, and surgery, Haukeland University Hospital Bergen.
John Sigurd Svendsen
John Sigurd is Professor in organic chemistry at the Faculty of Sciences at University of Tromsø. Dr. Svendsen received his Ph.D. from the University of Tromsø. He has been visiting scientist at Massachusetts Institute of Technology and brings research experience from work in medical biochemistry, synthetic organic chemistry and medicinal chemistry.
Mette holds a Post Doc position at University Hospital of North Norway and is Chief Operating Officer (COO) at Prophylix Pharma AS.She is one of the Founders of the company and has been working with FNAIT research for more than 10 years. Dr.Kjær received her Ph.D. in immunology from the University of Tromsø in 2008 and was engaged at St. Michaels Hospital, Toronto, Canada, in research on prophylactic treatment of FNAIT in an animal model.